both receptors negative or unknown); preoperative HER2-directed therapy (trastuzumab alone vs. trastuzumab plus an additional HER2-directed agent); and pathological nodal status after neoadjuvant ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow classification allows identification of ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

The development, pharmacology, safety, efficacy, and dosage and administration of trastuzumab are reviewed. The discovery of HER2 gene amplification in up to 30% of women with breast cancer led to ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

The binding between a biosimilar and ... across the life span of the products. Stability of Her2 under 37 ℃ was determined by SDS-PAGE and ELISA Human Her2, His Tag (Cat. No. HE2-H822R ) on ...

Patients with residual invasive HER2-positive early breast cancer after neoadjuvant systemic therapy have a poor prognosis. Adjuvant therapy with trastuzumab emtansine has shown improved outcomes.